The FDA has approved Besponsa (inotuzumab ozogamicin) for treating adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
The FDA has approved Besponsa (inotuzumab ozogamicin) for treating adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), a cancer that occurs when the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell.
ALL is a rapidly progressing type of cancer: the National Cancer Institute estimates that approximately 5970 people in the United states will be diagnosed with ALL in 2017, while 1440 will die as a result of the disease. Besponsa is intended to lower these odds by targeting and binding to B-cell ALL cancer cells that have the CD22 antigen and therefore restricting cancerous cells from growing.
“For adult patients with B-cell ALL whose cancer has not responded to initial treatment or has returned after treatment, life expectancy is typically low,” Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, said in a statement announcing the approval.
Besponsa was studied in a randomized trial of 326 patients who had relapsed or refractory B-cell ALL and had received 1 or 2 treatments before the study. The researchers then randomly selected patients to receive Besponsa for treatment or an alternative chemotherapy in order to measure the percentage of patients who demonstrated no evidence of disease and to calculate which patients had a full recovery of blood counts after treatment.
Of the total patients in the trial, 35.8% of those treated with Besponsa reached complete remission for a median 8 months, while of the patients who received chemotherapy, only 17.4% reached complete remission for a median of 4.9 months.
Despite Besponsa’s established efficacy, the treatment causes certain common side effects, including low levels of platelets, low levels of certain white blood cells, infection, anemia, fatigue, and fever.
“These patients have few treatments available and today’s approval provides a new, targeted treatment option,” Pazdur concluded.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Base-Edited T Cells Could Minimize Immunotherapy Complications in Leukemia, Study Suggests
November 18th 2023The use of base editing to generate universal, off-the-shelf CAR T cells is a promising approach for relapsed leukemia, with potential implications for the future of gene therapy.
Read More
Review Explores Link Between Tumor Burden, CAR T-Cell Therapy Efficacy
November 17th 2023A recent review aimed to characterize the relationship between tumor burden and clinical outcomes in patients treated with chimeric antigen receptor (CAR) T-cell therapy, highlighting the potential mechanisms of high tumor burden impacting CAR T-cell failure.
Read More